Jeff Yass’s BioAtla BCAB Stock Holding History

Jeff Yass’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-394	Closed	-$67.8K	–	12035
2024 Q1	$67.8K	Buy	+394	New	+$49K	﹤0.01%	11427
2023 Q4	–	Sell	-980	Closed	-$83.3K	–	12334
2023 Q3	$83.3K	Buy	+980	New	+$125K	﹤0.01%	11048
2023 Q2	–	Sell	-446	Closed	-$59.8K	–	12056
2023 Q1	$59.8K	Sell	446 -136	-23%	-$24.5K	﹤0.01%	11613
2022 Q4	$240K	Sell	582 -1,690	-74%	-$701K	﹤0.01%	9668
2022 Q3	$875K	Buy	+2,272	New	+$744K	﹤0.01%	6983
2022 Q2	–	Sell	-1,142	Closed	-$286K	–	12873
2022 Q1	$286K	Buy	+1,142	New	+$478K	﹤0.01%	10385

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's BCAB Position: Q2 2026 in Review

Jeff Yass sold out of BioAtla (BCAB) in Q2 2026, closing a stake of 781 shares — an estimated $6.29K sold.

Jeff Yass first reported a position in BCAB in Q2 2021 and held it in 20 quarters. The position peaked at $1.88M in Q4 2022. 21 funds tracked by Wall St. Rank hold BCAB as of Q2 2026.

Jeff Yass reported no remaining BioAtla position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 781 BioAtla shares in Q2 2026, an estimated $6.29K.
Jeff Yass first reported a position in BioAtla in Q2 2021 and held it in 20 quarters.
Jeff Yass's BioAtla position peaked at $1.88M in Q4 2022.
21 funds tracked by Wall St. Rank held BioAtla as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.